# Consolidated Financial Results for the Six Months Ended September 30, 2018 [Japanese GAAP] 

November 6, 2018
Company name: A\&D Company, Ltd.
Stock exchange listing: Tokyo Stock Exchange
Code number: 7745
URL: https://www.aandd.jp/
Representative: Yasunobu Morishima, President \& CEO
Contact: Sadao Ito, Director, Managing Executive Officer and Business Management HQ Executive
Phone: +81-48-593-1111
Scheduled date of filing quarterly securities report: November 13, 2018
Scheduled date of commencing dividend payments: December 10, 2018
Availability of supplementary briefing material on quarterly financial results: Available
Schedule of quarterly financial results briefing session: Scheduled (for institutional investors)
(Amounts of less than one million yen are truncated.)

1. Consolidated Financial Results for the Six Months Ended September 30, 2018 (April 1, 2018 to September 30, 2018)
(1) Consolidated Operating Results
(\% indicates changes from the previous corresponding period.)

|  | Net sales |  | Operating profit |  | Ordinary profit |  | Profit attributable to <br> parent company <br> shareholders |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Six months ended | Million yen | $\%$ | Million yen | $\%$ | Million yen | $\%$ | Million yen | $\%$ |
| September 30, 2018 | 21,003 | 10.0 | 348 | 10.7 | 401 | 11.1 | 305 | 75.3 |
| September 30, 2017 | 19,089 | 9.4 | 315 | - | 361 | - | 174 | - |

Note: Comprehensive income Six months ended September 30, 2018: ¥249 million [91.8 \%]
Six months ended September 30, 2017: ¥130 million [- \%]

|  | Basic earnings <br> per share |  |
| :--- | ---: | ---: |
| Diluted earnings <br> per share |  |  |
| Six months ended | Yen | Yen |
| September 30, 2018 | 14.93 | 14.89 |
| September 30, 2017 | 8.51 | 8.50 |

(2) Consolidated Financial Position

|  | Total assets | Net assets | Equity ratio |
| :--- | ---: | ---: | ---: |
|  | Million yen | Million yen | $\%$ |
| As of September 30, 2018 | 49,111 | 16,735 | 32.3 |
| As of March 31, 2018 | 47,048 | 15,939 | 33.6 |

Reference: Equity As of September 30, 2018: $¥ 15,880$ million
As of March 31, 2018: $¥ 15,813$ million

## 2. Dividends

|  | Annual dividends |  |  |  |  |  |  |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1st <br> quarter-end |  |  |  |  |  |  | 2nd <br> quarter-end | 3rd <br> quarter-end | Year-end | Total |
| Fiscal year ended March 31, 2018 | Yen | Yen | Yen | Yen | Yen |  |  |  |  |  |  |
| Fiscal year ending March 31, 2019 | - | 5.00 | - | 7.00 | 12.00 |  |  |  |  |  |  |
| Fiscal year ending March 31, 2019 <br> (Forecast) | - | 7.00 |  |  |  |  |  |  |  |  |  |

Note: Revision to the forecast for dividends announced most recently: Yes

## 3. Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2019 (April 1, 2018 to March

 31, 2019)(\% indicates changes from the previous corresponding period.)

|  | Net sales | Operating profit | Ordinary profit | Profit attributable <br> to parent company <br> shareholders | Basic earnings <br> per share |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Full year | Million yen | $\%$ | Million yen | $\%$ | Million yen | $\%$ | Million yen | $\%$ |
| Yen |  |  |  |  |  |  |  |  |

Note: Revision to the financial results forecast announced most recently: Yes

## * Notes:

(1) Changes in significant subsidiaries during the period under review: Yes
(Changes in specified subsidiaries accompanying changes to the scope of consolidation)
New: 1 company (Company name) HOLON CO., LTD.; Excluded: - companies (Company name) -
(2) Accounting policies adopted specially for the preparation of quarterly consolidated financial statements: Yes
(3) Changes in accounting policies, changes in accounting estimates and retrospective restatement

1) Changes in accounting policies due to the revision of accounting standards: No
2) Changes in accounting policies other than 1) above: No
3) Changes in accounting estimates: No
4) Retrospective restatement: No
(4) Total number of issued shares (common stock)
5) Total number of issued shares at the end of the period (including treasury stock):

September 30, 2018: 22,579,700 shares
March 31, 2018: 22,579,700 shares
2) Total number of treasury stock at the end of the period:

September 30, 2018: 2,091,285 shares
March 31, 2018: 2,091,280 shares
3) Average number of shares during the period:

Six months ended September 30, 2018: 20,488,419 shares Six months ended September 30, 2017: 20,488,420 shares
Note: The number of treasury stock eliminated when calculating the total number of treasury stock at the end of the period and the average number of shares during the period includes the Company's shares held by Trust \& Custody Services Bank, Ltd. (Trust E Account) as trust assets for the stock benefit trust system.

* These quarterly financial results are outside the scope of quarterly review by certified public accountants or audit corporations.
* Explanation of the proper use of financial results forecasts and other notes Forward-looking statements in this document, including financial results forecasts, are based on information available and certain assumptions deemed reasonable by the Company at present, and the Company does not guarantee their achievement. Actual business results, etc., may differ significantly due to various factors.

1. Qualitative Information on Quarterly Financial Results for the Period under Review ..... 2
(1) Business Results ..... 2
(2) Financial Position ..... 3
(3) Consolidated Financial Results Forecast and Other Forward-looking Information ..... 3
2. Quarterly Consolidated Financial Statements and Primary Notes ..... 4
(1) Quarterly Consolidated Balance Sheets ..... 4
(2) Quarterly Consolidated Statements of Income and Comprehensive Income ..... 6
Quarterly Consolidated Statements of Income Six Months Ended September 30 ..... 6
Quarterly Consolidated Statements of Comprehensive Income Six Months Ended September 30 ..... 7
(3) Notes to Quarterly Consolidated Financial Statements ..... 8
(Notes on going concern assumption) ..... 8
(Notes in the case of significant changes in shareholders' equity) ..... 8
(Changes in scope of consolidation or application of equity method) ..... 8
(Accounting policies adopted specially for the preparation of quarterly consolidated financial statements).. ..... 8
(Additional information) ..... 8
(Segment information, etc.) ..... 9
(Business combinations, etc.) ..... 11

## 1. Qualitative Information on Quarterly Financial Results for the Period under Review

(1) Business Results

The economic environment surrounding A\&D Company, Ltd. (the "Company") and its subsidiaries (collectively, the "Group") during the six months ended September 30, 2018 continued to recover moderately, as the employment and income environment remained on a recovery track with robust corporate earnings and capital investment, although future growth projections remained unclear due to various factors such as labor shortage stemming from a decline in the productive population in Japan.

In the global economy, despite overall strength centered on the United States, the Trump administration's hardline trade policy had a global impact. In China, some issues stemming from trade friction with the United States surfaced and the economy showed signs of a slowdown. In Europe, although concerns prevailed over the United Kingdom's Brexit issue and the Trump administration's conservatism, a moderate recovery was sustained primarily in the EU region.

Amid such circumstances, the Group focused on developing new products and cultivating new markets to respond to diverse and changing needs among customers and society. In addition, the Group strived to differentiate its products from those of competitors through ongoing active investments in development in growth sectors.

As a result, net sales for the six months ended September 30, 2018 were $¥ 21,003$ million (up $10.0 \%$ year-on-year), operating profit was $¥ 348$ million (up $10.7 \%$ year-on-year), ordinary profit was $¥ 401$ million (up $11.1 \%$ year-on-year), and profit attributable to parent company shareholders was $¥ 305$ million (up $75.3 \%$ year-on-year).

Business results by segment are as follows.

1) Measurement and Weighing Instruments Business

In Japan, sales related to semiconductor instruments recorded a significant increase mainly because HOLON CO., LTD. became a subsidiary, and sales of measurement and control simulation systems (DSP systems) also grew significantly against a backdrop of active capital investment and other factors in the automobile industry, while sales of weighing instruments remained robust primarily in the industrial measurement instrument area. In addition, as a result of curbing selling, general and administrative expenses, including research and development expenses, to a level on par with the same period of the previous fiscal year, profits also increased significantly.

In the Americas, although sales of balances and scales in weighing instruments did not go beyond those in the previous fiscal year, overall sales increased slightly year on year owing to contributions from sales of metal detectors, checkweighers and industrial measurement instruments. Sales of DSP systems remained strong due to factors such as stronger partnerships with local research and development institutions. However, profits decreased due to recording expenses intended to aid in future sales expansion.

In Asia and Oceania, in addition to stronger sales of a wide range of products centered on testing equipment in South Korea, special demand for metal detectors and checkweighers in Australia caused sales to rise.

As a result, sales in the measurement and weighing instruments business was $¥ 13,076$ million (up $15.7 \%$ year-on-year) and operating profit was $¥ 668$ million (up 263.8\% year-on-year).
2) Medical and Healthcare Business

In Japan, while special demand for fully automatic blood pressure monitors caused sales for medical instruments to increase, demand for blood pressure monitors for nursing use completed a cycle and sales declined. Sales of healthcare instruments dropped due to the lack of special demand from a large scale customer during the same period of the previous fiscal year.

In the Americas, although additional sales were recorded from a medical instruments business that was acquired in Canada during the previous fiscal year, high sales of low-margin products in the United States
caused profits to decrease.
In Europe, while sales were higher in Russia, aggressive advertising activities to combat intense competition in the blood pressure measurement market due to the entrance of Chinese firms resulted in lower profits.

As a result, net sales in the medical and healthcare business were $¥ 7,926$ million (up $1.7 \%$ year-on-year) and operating profit was $¥ 750$ million (down $33.0 \%$ year-on-year).

## (2) Financial Position

(Assets, liabilities and net assets)
The Partial Amendments to Accounting Standard for Tax Effect Accounting (Accounting Standards Board of Japan ("ASBJ") Statement No. 28, February 16, 2018), etc., have been applied from the beginning of the first quarter ended June 30, 2018. These accounting standards, etc. have been applied retrospectively to figures for the previous fiscal year for comparison and analysis in these explanations on financial position.

Total assets as of September 30,2018 were $¥ 49,111$ million, an increase of $¥ 2,062$ million compared to the end of the previous fiscal year. This is due to an increase of $¥ 1,463$ million in current assets owing to factors such as higher inventory despite a decrease in bills and accounts receivable, and an increase of $¥ 599$ million in fixed assets owing to factors such as an increase in goodwill in intangible fixed assets.

Total liabilities as of September 30 , 2018 were $¥ 32,376$ million, an increase of $¥ 1,267$ million compared to the end of the previous fiscal year. This is primarily attributable to an increase of $¥ 682$ million in fixed liabilities caused by an increase in long-term debt, in addition to an increase of $¥ 584$ million in current liabilities owing to an increase in short-term debt.

Net assets as of September 30,2018 were $¥ 16,735$ million, an increase of $¥ 795$ million compared to the end of the previous fiscal year. This was due to an increase of $¥ 160$ million in shareholders’ equity owing to an increase in retained earnings resulting from recording profit attributable to parent company shareholders in excess of payment of dividends as well as a decrease of $¥ 93$ million in accumulated other comprehensive income due mainly to a decline in foreign currency translation adjustments, while non-controlling shareholders' equity increased by $¥ 729$ million primarily because HOLON CO., LTD. became a subsidiary.
(3) Consolidated Financial Results Forecast and Other Forward-looking Information

In view of recent business trends and other factors, the Company revised its consolidated financial results forecast for the fiscal year ending March 31, 2019 that was announced on August 3, 2018. For details, please see the "Notice Regarding Difference Between Financial Results Forecast and Financial Results for the Six Months Ended September 30, 2018 and Revision of Dividends of Surplus (Interim Dividends) and Full-year Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2019," separately announced today.

## 2. Quarterly Consolidated Financial Statements and Primary Notes

(1) Quarterly Consolidated Balance Sheets
(Million yen)
As of March 31, 2018
As of September 30, 2018

| Assets |  |  |
| :---: | :---: | :---: |
| Current assets |  |  |
| Cash and deposits | 8,016 | 7,911 |
| Bills and accounts receivable | 12,980 | 12,180 |
| Marketable securities | 50 | - |
| Products | 6,359 | 7,333 |
| Unfinished goods | 2,255 | 3,225 |
| Raw materials and supplies | 3,168 | 3,394 |
| Other | 827 | 1,077 |
| Allowance for doubtful accounts | (83) | (84) |
| Total current assets | 33,574 | 35,037 |
| Fixed assets |  |  |
| Tangible fixed assets |  |  |
| Land | 4,099 | 4,184 |
| Other, net | 4,998 | 5,303 |
| Total tangible fixed assets | 9,097 | 9,488 |
| Intangible fixed assets |  |  |
| Goodwill | 146 | 487 |
| Other | 2,039 | 1,984 |
| Total intangible fixed assets | 2,186 | 2,471 |
| Investments, etc. | 2,189 | 2,113 |
| Total fixed assets | 13,473 | 14,073 |
| Total assets | 47,048 | 49,111 |
| Liabilities |  |  |
| Current liabilities |  |  |
| Bills and accounts payable | 4,738 | 4,904 |
| Short-term debt | 12,193 | 12,715 |
| Long-term borrowings to be repaid within one year | 3,110 | 3,416 |
| Accrued corporate taxes, etc. | 337 | 325 |
| Provision for bonuses | 957 | 1,017 |
| Provision for product warranties | 142 | 172 |
| Other | 4,169 | 3,683 |
| Total current liabilities | 25,650 | 26,235 |
| Fixed liabilities |  |  |
| Corporate bonds | 15 | 10 |
| Long-term debt | 3,929 | 4,543 |
| Provision for product warranties | 89 | 80 |
| Debt related to retirement benefits | 847 | 958 |
| Provision for directors' share benefits | 25 | 29 |
| Other | 551 | 519 |
| Total fixed liabilities | 5,458 | 6,140 |
| Total liabilities | 31,108 | 32,376 |


|  | As of March 31, 2018 | As of September 30, 2018 |
| :---: | :---: | :---: |
| Net assets |  |  |
| Shareholders' equity |  |  |
| Common stock | 6,388 | 6,388 |
| Capital surplus | 6,404 | 6,404 |
| Retained earnings | 5,798 | 5,958 |
| Treasury stock | $(1,136)$ | $(1,136)$ |
| Total shareholders' equity | 17,454 | 17,614 |
| Accumulated other comprehensive income |  |  |
| Unrealized gains on other marketable securities | 25 | 29 |
| Foreign currency translation adjustments | $(2,307)$ | $(2,358)$ |
| Accumulated adjustment on retirement benefits | 642 | 594 |
| Total accumulated other comprehensive income | $(1,640)$ | $(1,734)$ |
| Non-controlling shareholders' equity | 125 | 855 |
| Total net assets | 15,939 | 16,735 |
| Total liabilities and net assets | 47,048 | 49,111 |

## (2) Quarterly Consolidated Statements of Income and Comprehensive Income

Quarterly Consolidated Statements of Income
Six Months Ended September 30
(Million yen)

|  | For the six months ended September 30, 2017 | For the six months ended September 30, 2018 |
| :---: | :---: | :---: |
| Net sales | 19,089 | 21,003 |
| Cost of sales | 10,532 | 11,890 |
| Gross profit | 8,556 | 9,112 |
| Selling, general and administrative expenses | 8,241 | 8,763 |
| Operating profit | 315 | 348 |
| Non-operating income |  |  |
| Interest income | 26 | 34 |
| Investment gain on equity method | 1 | 86 |
| Exchange gain | 47 | - |
| Rent received | 15 | 15 |
| Other | 73 | 107 |
| Total non-operating income | 164 | 244 |
| Non-operating expenses |  |  |
| Interest expense | 94 | 109 |
| Exchange loss | - | 15 |
| Other | 23 | 67 |
| Total non-operating expenses | 118 | 192 |
| Ordinary profit | 361 | 401 |
| Extraordinary income |  |  |
| Gain on step acquisitions | - | 498 |
| Gain on sale of fixed assets | 1 | 1 |
| Total extraordinary income | 1 | 500 |
| Extraordinary loss |  |  |
| Loss on sale of fixed assets | 0 | 3 |
| Loss on disposal of fixed assets | 0 | 0 |
| Impairment loss | - | 461 |
| Loss on valuation of investment securities | - | 9 |
| Total extraordinary loss | 1 | 474 |
| Profit before taxes | 361 | 427 |
| Corporate, inhabitant and business taxes | 204 | 217 |
| Corporate tax adjustments | (22) | (131) |
| Total corporate taxes | 181 | 86 |
| Profit | 179 | 340 |
| Profit attributable to non-controlling shareholders' equity | 4 | 35 |
| Profit attributable to parent company shareholders | 174 | 305 |

Quarterly Consolidated Statements of Comprehensive Income
Six Months Ended September 30
(Million yen)

|  | For the six months <br> ended September 30, 2017 | For the six months <br> ended September 30, 2018 |
| :--- | ---: | ---: | ---: |
| Profit | 179 | 340 |
| Other comprehensive income | $\mathbf{c}$ |  |
| Unrealized gains on other marketable securities | $(20)$ | 4 |
| Foreign currency translation adjustments | $(33)$ | $(48)$ |
| Adjustment related to retirement benefits | 0 | $(47)$ |
| Equity equivalent for equity method affiliates | $(49)$ | 0 |
| Total other comprehensive income | 130 | $(91)$ |
| Comprehensive income <br> (Breakdown) <br> Comprehensive income attributable to parent company <br> shareholders | 126 | 249 |
| Comprehensive income attributable to non-controlling <br> shareholders' equity | 3 | 212 |

(3) Notes to Quarterly Consolidated Financial Statements
(Notes on going concern assumption)
Not applicable.
(Notes in the case of significant changes in shareholders' equity)
Not applicable.
(Changes in scope of consolidation or application of equity method)

| For the six months ended September 30, 2018 |
| :--- |
| (Significant changes in scope of consolidation) |
| During the first quarter ended June 30, 2018, the Company acquired additional shares in HOLON CO., |
| LTD., which was a former equity method affiliate. As a result, the said company was consolidated effective |
| June 30,2018. |

(Accounting policies adopted specially for the preparation of quarterly consolidated financial statements)

|  | For the six months ended September 30, 2018 |
| :--- | :--- |
| Calculation of tax <br> expenses | Tax expenses for certain consolidated subsidiaries are calculated by reasonably <br> estimating the effective tax rate after tax effect accounting to be applied to profit <br> before taxes for the fiscal year, which includes the second quarter under review, <br> and multiplying profit before taxes by the estimated effective tax rate thus <br> obtained. |

(Additional information)

| For the six months ended September 30, 2018 |
| :--- |
| Application of Partial Amendments to Accounting Standard for Tax Effect Accounting, etc. |
| The Company applied the Partial Amendments to Accounting Standard for Tax Effect Accounting (ASBJ |
| Statement No. 28, February 16, 2018), etc. from the beginning of the first quarter ended June 30, 2018. |
| Deferred tax assets are presented under "investments, etc.," and deferred tax liabilities are presented under |
| fixed liabilities. |

## (Segment information, etc.)

## [Segment information]

I. For the six months ended September 30, 2017

1. Information on net sales and profit (loss) by reportable segment
(Million yen)

|  | Measurement and Weighing Instruments Business |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: |
|  | Japan | Americas | Europe | Asia and <br> Oceania | Total |
| Net sales <br> Net sales to outside <br> customers | 7,766 | 1,622 | 405 | 1,504 | 11,298 |
| Inter-segment net sales <br> or transfers | 1,080 | 13 | 27 | 1,281 | 2,401 |
| Total | 8,846 | 1,635 | 432 | 2,785 | 13,700 |
| Segment profit (loss) | 12 | 52 | $(4)$ | 123 | 183 |


|  | Medical and Healthcare Business |  |  |  |  |  | Adjustment <br> (Note 1) |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Consolidation <br> (Note 2) |  |  |  |  |  |  |
| Net sales <br> Net sales to outside <br> customers | 2,425 | 2,126 | 3,054 | 184 | 7,790 | - | 19,089 |
| Inter-segment net sales <br> Or transfers | 3,410 | - | - | 2,620 | 6,030 | $(8,432)$ | - |
| Total | 5,836 | 2,126 | 3,054 | 2,804 | 13,821 | $(8,432)$ | 19,089 |
| Segment profit (loss) | 831 | $(59)$ | 245 | 103 | 1,120 | $(989)$ | 315 |

Notes: 1. The adjustment of $¥(989)$ million in segment profit (loss) includes corporate expenses of $¥(784)$ million not allocated to reportable segments. Corporate expenses are primarily general and administrative expenses for management departments.
2. Segment profit (loss) is adjusted with operating profit on the quarterly consolidated statements of income.
2. Information on impairment loss or goodwill, etc., for fixed assets by reportable segment Not applicable.
II. For the six months ended September 30, 2018

1. Information on net sales and profit (loss) by reportable segment
(Million yen)

|  | Measurement and Weighing Instruments Business |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: |
|  | Japan | Americas | Europe | Asia and <br> Oceania | Total |
| Net sales <br> Net sales to outside <br> customers | 9,210 | 1,663 | 411 | 1,791 | 13,076 |
| Inter-segment net sales <br> or transfers | 1,379 | 91 | 19 | 1,308 | 2,798 |
| Total | 10,590 | 1,754 | 430 | 3,100 | 15,875 |
| Segment profit (loss) | 581 | $(71)$ | $(29)$ | 188 | 668 |


|  | Medical and Healthcare Business |  |  |  |  | Adjustment <br> (Note 1) | Consolidation <br> (Note 2) |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Japan | Americas | Europe | Asia and <br> Oceania | Total |  |  |
| Net sales <br> Net sales to outside <br> customers | 2,274 | 2,292 | 3,179 | 179 | 7,926 | - | 21,003 |
| Inter-segment net sales <br> or transfers | 3,938 | - | - | 3,153 | 7,091 | $(9,890)$ | - |
| Total | 6,212 | 2,292 | 3,179 | 3,333 | 15,018 | $(9,890)$ | 21,003 |
| Segment profit (loss) | 570 | $(164)$ | 109 | 236 | 750 | $(1,070)$ | 348 |

Notes: 1. The adjustment of $¥(1,070)$ million in segment profit (loss) includes corporate expenses of $¥(764)$ million not allocated to reportable segments. Corporate expenses are primarily general and administrative expenses for management departments.
2. Segment profit (loss) is adjusted with operating profit on the quarterly consolidated statements of income.
2. Information on impairment loss or goodwill, etc., for fixed assets by reportable segment
(Significant changes in amount of goodwill)
In the measurement and weighing instruments business, due to the additional acquisition of shares in HOLON CO., LTD., a former equity method affiliate, the said company has been included in the scope of consolidation as a consolidated subsidiary, with a deemed acquisition date of June 30, 2018. The amount of increase in goodwill as a result of this consolidation is $¥ 844$ million.

As a result of careful consideration of the recoverability of goodwill based on the future business plans, etc., of HOLON CO., LTD., goodwill has been reduced to the recoverable amount and an impairment loss of $¥ 461$ million has been recorded.
(Business combinations, etc.)
Business combination through acquisition
(1) Summary of business combination

1) Name and business of acquiree

Name of acquiree: HOLON CO., LTD.
Business: Development and manufacturing of semiconductor electron beam measurement and testing equipment
2) Main reason for business combination

To maximize use of both companies' resources toward further improvement in corporate value of both companies.
3) Date of business combination June 29, 2018
4) Legal form of business combination Share acquisition by cash
5) Name of entity after business combination Unchanged.
6) Ratio of voting rights acquired Voting rights held prior to business combination: 30.58\% Additional voting rights acquired on date of business combination: 20.42\% Voting rights after acquisition:
51.00\%
7) Grounds for determining acquirer The Company's acquisition of shares with cash as consideration.
(2) Period of the acquiree's financial results included in the quarterly consolidated statements of income for the period under review
From July 1, 2018 to September 30, 2018. As the acquiree was the Company's equity method affiliate, business results from April 1, 2018 to June 30, 2018 are recorded as investment gain on equity method.
(3) Breakdown of acquisition cost and type of consideration of acquiree

Fair value on the date of business combination of HOLON CO., LTD. held prior $¥ 939$ million to business combination
Fair value of common stock of HOLON CO., LTD. acquired on the date of $¥ 627$ million business combination
Acquisition cost $\quad ¥ 1,567$ million
(4) Difference between total acquisition cost of acquiree and sum of acquisition costs of individual transactions up to the acquisition date
Gain on step acquisitions of $¥ 498$ million was incurred.
(5) Amount, reason for incurrence, amortization method and amortization period for goodwill

1) Amount of goodwill ¥844 million
2) Reason for incurrence

As the acquisition cost exceeded the net amount of assets accepted and liabilities assumed, the excess amount has been recorded as goodwill.
3) Amortization method and amortization period Amortization via the straight-line method over five years A portion of goodwill has been reduced to the recoverable amount, and the said amount of reduction has been recorded as an impairment loss.

